McKesson Corporation (MCK)
Health Care2 articles
Price chart
McKesson Corporation (MCK) overview
McKesson is one of the largest U.S. pharmaceutical distributors. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
McKesson Corporation trades on the NYSE under the ticker symbol MCK. As of the most recent market data, the stock was priced around $885.32, down 0.90% on the session, giving McKesson Corporation a market capitalization of roughly $103.22B.
Over the past 52 weeks, MCK has traded between $682.35 and $999.00. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 24.0, a common gauge of how richly the market prices the company's earnings. McKesson Corporation also pays a dividend, currently yielding around 42.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MCK
As one of the larger companies in the Health Care sector, McKesson Corporation is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch MCK for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, McKesson Corporation's size means its share-price moves can also nudge the index as a whole, making MCK a stock that even index investors pay attention to.
Market Mood
Latest MCK news
McKesson (MCK) Director Sells $268,589 in Shares
Bradley Lerman, a director at McKesson (MCK), sold shares worth $268,589. This sale highlights insider trading activity within the company. Selling shares by company insiders can sometimes signal confidence levels in the business, affecting market perceptions. Investors often monitor insider transactions for insights about future company performance.
Read More: McKesson (MCK) Director Sells $268,589 in Shares
FDA Commissioner Marty Makary Resigns Amid Pressure
FDA Commissioner Marty Makary has resigned from his position. His departure comes amid reported pressures related to the Trump administration. The implications of this resignation on FDA operations remain unclear, but it may affect regulatory processes involved in drug approvals and public health initiatives. This situation could have a potential impact on pharmaceutical stocks and investor sentiment regarding the FDA's regulatory environment.
Read More: FDA Commissioner Marty Makary Resigns Amid PressureMore Health Care stocks
Frequently asked questions
Is McKesson Corporation in the S&P 500?
Yes. McKesson Corporation (MCK) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is MCK in?
McKesson Corporation is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest MCK news?
This page collects recent McKesson Corporation (MCK) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is McKesson Corporation's stock price?
As of the most recent market data, McKesson Corporation (MCK) traded at approximately $885.32. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is McKesson Corporation's market cap?
McKesson Corporation has a market capitalization of roughly $103.22B, based on its most recent share price and shares outstanding.
What is MCK's P/E ratio?
MCK trades at a trailing price-to-earnings ratio of about 24.0. The P/E ratio compares a company's share price to its earnings per share.